



This analysis examines the new, typically innovative pharmaceutical technologies that have been submitted but do not yet make the final decision by the National Health Insurance Fund of Hungary (NHIFA) and Ministry of Human Capacities (MoHC). This special edition has been updated with the 11 month event since the [previous](#) report. The previous marked in red are also represented to make the changes clear visible. The analysis focuses only on the technologies that passed the standard 90 days period and bases on the data published by the NHIFA on July 19, 2019. The validity of published data has not been investigated by Healthware.

Number of the ongoing submission procedures by reimbursement category (brands)²




Almost all new products (~77%) (~83%) targeted a 100% reimbursement category.

In 37 (38) SKUs the exact Indications are unknown.




Average procedure length by reimbursement category (days)²



Number of the ongoing submission procedures by ATC5 codes²


ATC5	Name	Brands	SKUs
L01XE	Protein kinase inhibitors	6	10
L01XC	Monoclonal antibodies	5	10
V06D	Other nutrients	2	7
L04AC	Interleukin inhibitors	4	6
L01XX	Other antineoplastic agents	2	5
M03BX	Muscle relaxants, other centrally acting agents	2	4
L04AA	Selective immunosuppressants	2	4
C09DX	Angiotensin II antagonists, other combinations	1	4
L01BB	Purine analogues	1	3
B02BD	Blood coagulation factors	2	2
C10AX	Other lipid modifying agents	2	2
B01AF	Direct factor Xa inhibitors	1	2
B03AC	Iron, parenteral preparations	1	2
J05AX	Other direct acting antivirals	1	2
L02BB	Anti-androgens	1	2
L03AB	Interferons	1	2
N04BC	Dopamine agonists	1	2
R03AK	Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics	1	2
A10AB	Combinations of oral blood glucose lowering drugs	1	1
B01AC	Platelet aggregation inhibitors excl. heparin	1	1
B02BX	Other systemic hemostatics	1	1
C02KX	Antihypertensives for pulmonary arterial hypertension	1	1
C03DA	Aldosterone antagonists	1	1
C07FX	Beta blocking agents, other combinations	1	1
C09DB	Angiotensin II receptor blockers (ARBs) and calcium channel blockers	1	1
D07AD	Corticosteroids, very potent (group IV)	1	1
G03DA	Pregnen (4) derivatives	1	1
G04BX	Other urologicals	1	1
J01MA	Fluoroquinolones	1	1
J05AP	Antivirals for treatment of HCV infections	1	1
L01CD	Taxanes	1	1
L02BX	Other hormone antagonists and related agents	1	1
L04	Immunosuppressants	1	1
N02CX	Other antimigraine preparations	1	1
N05AE	Indole derivatives	1	1
S01XA	Other ophthalmologicals	1	1
V04CJ	Test for thyroidea function	1	1
J05AR	Antivirals for treatment of HIV infections, combinations	1	1
Total		56	91

Average procedure length by ATC main groups (days)²



Top 3 applicants by the number of brands and SKUs²

Top 3 ATC main group by the number of brands and SKUs²




During the NHIFA co-ordinated period, the financing structure for the technology will be determined on the basis of submitted and agreed HTA, BIA and medical considerations. The final decision is taken by a Committee coordinated by the Ministry. Actual timelines of ongoing procedures are the following:

- 58% are waiting for the final decision more than 90 days.
- NHIFA made a positive preliminary decision on 60% of the submissions.
- The average procedure time of the analyzed products is 270 days (min-max: 95 and 879 days).
- The average procedure time of NHIFA is 221 days (min-max: 24 and 605 days).
- The average procedure time of MoHC is 87 days (min-max: 36 and 279 days).
- 56 new brands are waiting for ministerial decision at this moment.

According to a new legislation, which has been taken effect on 01.01.2018, NHIFA has to make final decision of a submission in 365 days. Expectations are that average procedure time of NHIFA is going to decrease. In practice, applicants usually discontinue their ongoing submission procedure around the 365th day, instead of being rejected. This can be explained by the fact that in this case patients can apply for named patients reimbursement to get the pharmaceutical technologies they need. 15 such cases were found, where applicants discontinued their ongoing procedures just before the 365th day. Ministries' discussions of ongoing procedures of 56 new brands are currently occurring. The most frequent indications are neoplastic diseases as it was found in the previous two reports, too.

With further questions, [please contact us!](#)



¹ NHIFA: National Health Insurance Fund of Hungary
² Healthware analysis based on NHIFA data
³ Standard official process period of NHIFA